GAP posted a strong earnings beat on August 27, rallied 11% the following session, and is now up 9% on the week — yet short interest still runs at nearly 8% of free float, and options traders have swung firmly to the bullish side.
The earnings reaction inverted the setup entirely. Pre-print, shorts had been rebuilding and analysts were cutting targets. The stock's 11% surge on August 27 caught bears positioned for bad news. Short interest did tick down sharply on August 31 — falling to roughly 29.6 million shares — but the one-week reading still shows a 4.4% net increase. Bears added before the print and have only partially unwound. At 7.9% of free float, the short position remains meaningful and above where it sat through most of July and early August. The prior notes documented bears rebuilding quietly into the catalyst; that catalyst delivered against them, yet the unwind has been measured rather than panicked.
Options positioning has flipped hard since the earnings-eve setup. The put/call ratio has dropped to 0.84 — nearly 2.1 standard deviations below its 20-day average of 0.92. That is a sharp reversal from the defensive posture seen heading into the print, when the PCR briefly touched 1.00. Calls are now significantly outpacing puts, reflecting a market that is chasing the move rather than hedging against it. The borrow market remains relaxed: availability is around 512% of outstanding short interest, meaning there are ample shares to borrow for anyone still building a short thesis, and cost to borrow has barely moved, now at 0.53%. There is no squeeze dynamic forcing shorts out — those who are staying in have the room to hold.
The analyst response to the earnings beat was unanimous but calibrated. Every firm raised its price target. Goldman Sachs lifted to $27 from $25, upgrading from a prior trim that had cut to $25 just six days earlier on August 21 — a notable reversal at a bellwether firm. UBS went furthest, raising to $42 from $40, the most aggressive target in the group. Morgan Stanley, Barclays, and Wells Fargo all raised targets while holding Equal-Weight ratings, collectively signalling that the beat was real but the re-rating has limits. The consensus mean target is now $26.74, roughly 21% above the current $22.00 close. The bull case centres on eight consecutive quarters of positive comp sales, potential for double-digit operating margins, and a valuation still trading at a discount — PE near 8.4x and EV/EBITDA at 5.8x. Bears point to tariff headwinds, ongoing Athleta weakness, and the dependence on Old Navy. The ORTEX short score sits at 57.9, roughly mid-range and little changed over the past two weeks — no conviction shift either way from the systematic lens.
The Fisher family ownership picture has a new wrinkle worth flagging. William S. Fisher — one of three founding-family members on the Schedule 13D activist register — filed on August 31 showing his stake fell from 16.3% to 14.6%, a reduction of roughly 6 million shares. All three Fisher siblings (John, Robert, and William) carry active 13D filings, meaning they are on record as holders with potential influence over strategic direction. William's trim is the latest in a gradual step-down: Robert filed in June showing a move from 15.2% to 14.6%. The combined family stake still dominates the register at well above 40% collectively, but the direction of travel is steady reduction. As always with 13D/G disclosures, stakes are as-last-disclosed around the 5% threshold, and the data reflects filed positions rather than real-time holdings.
The next scheduled earnings date is November 19. Between now and then, the question is whether the post-earnings short position — still nearly 8% of float — continues to bleed out gradually, or whether shorts find a new reason to rebuild as the tariff and margin narrative evolves through the back half of the year.
See the live data behind this article on ORTEX.
Open GAP on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
